4,4-二甲基-7-硝基异喹啉-1,3-二酮 | 14576-21-7

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 4,4-二甲基-7-硝基异喹啉-1,3-二酮
• 中文别名: 1,3(2H,4H)-异喹啉二酮,4,4-二甲基-7-硝基-
• 英文名称: 4,4-dimethyl-7-nitro-2H,4H-isoquinoline-1,3-dione
• 英文别名: 4,4-dimethyl-7-nitroisoquinoline-1,3(2H,4H)-dione；4,4-Dimethyl-7-nitrohomophthalimid；4,4-dimethyl-7-nitro-2H-3,4-dihydro-isoquinolin-1,3-dione；4,4-dimethyl-7-nitro-4H-isoquinoline-1,3-dione；1,3(2H,4H)-Isoquinolinedione, 4,4-dimethyl-7-nitro-；4,4-dimethyl-7-nitroisoquinoline-1,3-dione
• CAS: 14576-21-7
• 化学式: C₁₁H₁₀N₂O₄
• 分子量: 234.211
• InChiKey: IJRTYXJAHMLEJN-UHFFFAOYSA-N

物化性质

• 熔点：
  209-211 °C(Solv: ethanol (64-17-5))
• 沸点：
  444.3±45.0 °C(Predicted)
• 密度：
  1.334±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  92
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4,4-二甲基-7-硝基异喹啉-1,3-二酮 在 10percent Pd/C 氢气 作用下， 以 甲醇 为溶剂， 反应 1.5h， 以98%的产率得到7-amino-4,4-dimethyl-2H,4H-isoquinoline-1,3-dione
  参考文献：
  名称：

  Discovery of 2-Phenylamino-imidazo[4,5-h]isoquinolin-9-ones:  A New Class of Inhibitors of Lck Kinase

  摘要：

  An imidazo[4,5-h]isoquinolin-7,9-dione (1) was identified as an adenosine 5'-triphosphate competitive inhibitor of lck by high throughput screening. Initial structure-activity relationship studies identified the dichlorophenyl ring and the imide NH as important pharmacophores. A binding model was constructed to understand how 1 binds to a related kinase, lick. These results suggested that removing the gem-dimethyl group and flattening the ring would enhance activity. This was realized by converting 1 to the imidazo[4,5-h]isoquinolin-9-one (20), resulting in an 18-fold improvement in potency against lck and a 50-fold increase in potency in a cellular assay.

  DOI：

  10.1021/jm020113o
• 作为产物：
  描述：

  4,4-二甲基异喹啉-1,3(2H,4H)-二酮 在 硝酸 作用下， 以 硫酸 为溶剂， 生成 4,4-二甲基-7-硝基异喹啉-1,3-二酮
  参考文献：
  名称：

  Pyrrolobenzimidazoles for treating heart or circulatory diseases

  摘要：

  吡咯并咪唑类化合物，其制备方法以及用于治疗冠状动脉不足、心力衰竭、血液循环障碍和闭塞性疾病的药物组合物。新的吡咯并咪唑类化合物的结构式为##STR1##其中R.sub.1为氢、烷基、烯基或环烷基，R.sub.2为氢、烷基、烯基、氰基或取代的羰基，或R.sub.1和R.sub.2一起代表环烷基或形成烷基亚甲基或环烷基亚甲基，X为价键，C.sub.1-C.sub.4烷基或乙烯基，T为氧或硫，Py为吡啶基或取代的吡啶基，包括其互变异构体和生理上可接受的盐。

  公开号：

  US04666923A1

文献信息

• Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
  申请人：Kelly G. Michael

  公开号：US20050277643A1

  公开（公告）日：2005-12-15

  Amine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.

  抗氨化合物的公开披露，其化学式如下所示： 这些化合物可以制备成药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，例如疼痛、炎症、创伤等。
• 吡唑并嘧啶化合物及制备方法与制备抗癌症药物的应用
  申请人：苏州锐明新药研发有限公司

  公开号：CN110950868B

  公开（公告）日：2022-05-13

  本发明提供了式(I)所示的一类吡唑并嘧啶化合物或其药学可接受的盐及其制备方法和在制备治疗或预防癌症的药物中的应用。该类化合物是PI3K抑制剂，具有优异的抑制活性，有望用于多种恶性肿瘤的治疗。
• Antithrombotic quinoxazolines
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US06200976B1

  公开（公告）日：2001-03-13

  Quinoxazolines having antithrombotic activity. Exemplary of those disclosed are: 4-{[6-(N-carboxymethyl-quinolin-8-yl-sulphonylamino)-1-methyl-2-oxo-1,2-dihydroquinoxalin-3-yl]-methyl}-benzamidine, 4-{[6-(1-(N-cyclopentyl-carboxymethylcarbonylamino)-cyclo-propyl)-1-methyl-2-oxo-1,2-dihydroquinoxalin-3-yl]-methyl}-benzamidine, and 4-{[7-(N-carboxymethylaminocarbonyl-ethylamino)-4-methyl-quinolin-2-yl]-oxo}-benzamidine.

  奎诺沙唑啉具有抗血栓活性。其中一些示例包括：4-〔6-(N-羧甲基喹啉-8-基磺胺基)-1-甲基-2-氧代-1,2-二氢喹啉-3-基〕-甲基-苯甲酰胺，4-〔6-(1-(N-环戊基-羧甲基羰基氨基)-环丙基)-1-甲基-2-氧代-1,2-二氢喹啉-3-基〕-甲基-苯甲酰胺，以及4-〔7-(N-羧甲基氨基甲酰基乙基氨基)-4-甲基喹啉-2-基〕-氧代-苯甲酰胺。
• Heterocyclic compounds useful as inhibitors of tyrosine kinases
  申请人：——

  公开号：US20020016460A1

  公开（公告）日：2002-02-07

  Disclosed are novel compounds of formula (I): 1 wherein Ar 1 , R a , R 4 , R 5 , X and Y are defined below, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases associated with such kinases, for example, diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are processes for preparing these compounds, novel intermediates useful in these processes and compositions comprising compounds of the formula (I).

  揭示了式（I）的新化合物：其中Ar1、Ra、R4、R5、X和Y的定义如下，这些化合物可用作某些蛋白酪氨酸激酶的抑制剂，因此可用于治疗与这些激酶相关的疾病，例如由于细胞不当增殖而导致的疾病，包括自身免疫疾病、慢性炎症性疾病、过敏疾病、移植排斥和癌症，以及由脑缺血引起的疾病，如中风。还披露了制备这些化合物的方法，这些方法中有用的新中间体以及包含式（I）化合物的组合物。
• Pyrrolobenzimidazoles for treating heart or circulatory diseases
  申请人：Boehringer Mannheim GmbH

  公开号：US04666923A1

  公开（公告）日：1987-05-19

  Pyrrolobenzimidazoles, processes for the preparation thereof and pharmaceutical compositions thereof for the treatment of coronary insufficiencies, cardiac failure, blood circulatory disturbances and occlusive diseases. The new pyrrolobenzimidazoles are of the formula ##STR1## wherein R.sub.1 is hydrogen, alkyl, alkenyl or cycloalkyl, R.sub.2 is hydrogen, alkyl, alkenyl, cyano or a substituted carbonyl or R.sub.1 and R.sub.2 together represent cycloalkylene or form alkylidene or cycloalkylidene, X is a valency bond, C.sub.1 -C.sub.4 alkylene or vinylene, T is oxygen or sulphur and Py is pyridyl or substituted pyridyl and including the tautomers thereof and the physiologically acceptable salts thereof.

  吡咯并咪唑类化合物，其制备方法以及用于治疗冠状动脉不足、心力衰竭、血液循环障碍和闭塞性疾病的药物组合物。新的吡咯并咪唑类化合物的结构式为##STR1##其中R.sub.1为氢、烷基、烯基或环烷基，R.sub.2为氢、烷基、烯基、氰基或取代的羰基，或R.sub.1和R.sub.2一起代表环烷基或形成烷基亚甲基或环烷基亚甲基，X为价键，C.sub.1-C.sub.4烷基或乙烯基，T为氧或硫，Py为吡啶基或取代的吡啶基，包括其互变异构体和生理上可接受的盐。